Pembrolizumab Unlikely to Be Cost-Effective for Previously Treated Triple-Negative Breast Cancer
A cost-effectiveness analysis indicates that pembrolizumab is unlikely to be a cost-effective option compared with chemotherapy for previously treated triple-negative ...










